Belite Bio Inc ADR BLTE
News
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
Belite Bio to Participate in Three Upcoming Investor Conferences
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
Belite Bio to Present at the JonesHealthcare Seaside Summit